Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03417154
Title Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Masonic Cancer Center, University of Minnesota
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Minnesota Masonic Cancer Center Minneapolis Minnesota 55455 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field